Financials

News Discussions Technicals Forecast Seasonals

2315 fundamentals

Overview Statements Statistics Dividends Earnings Revenue

An in-depth look to BIOCYTOGEN PHARMACEUTICALS (BEIJING operating, investing, and financing activities

2315 free cash flow for H2 24 is 170.34 M HKD. For 2024, 2315 free cash flow was 169.1 M HKD and operating cash flow was 209.36 M HKD.

Cash from operating activities

Cash from investing activities

Cash from financing activities

Income statement Balance sheet Cash flow

Currency: HKD

TTM

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—